Bravecto® chewable tablets for dogs
Bravecto Chewable Tablets is an ectoparasiticide treatment for dogs that contains the active ingredient fluralaner. It is a flea and tick treatment of the isoxazoline class for dogs with a duration of effect of 12 weeks*.
Presentation
Bravecto is a pork-flavoured chewable tablet presented in child resistant, foil wrapped, packs of either one or two tablets.
Active ingredients
Bravecto is an ectoparasiticide treatment for dogs that contains the active ingredient fluralaner.
Target species
Dogs
Indications for use
Bravecto has an immediate and persistent activity against both fleas and ticks and the prolonged activity can aid compliance and helps in the control of fleas in the house. Bravecto can be used at all life stages – including during breeding, pregnancy and lactation and in puppies from 8 weeks of age and/ or weighing 2 kg or more.
It is the only flea and tick treatment of the Isoxazoline class with an extended duration of effect of 12 weeks*.
Bravecto Chew can also be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Bravecto remains effective after swimming and bathing / shampooing.
Packaging
Bravecto is presented in child resistant packaging. It comes in a range of sizes to suit toy, small, medium and large dogs.
Legal Category
POM-V
For full information please refer to the product data sheet. Further information is available on request.
Use Medicines Responsibly. For more information please refer to the Responsible Use sections of the NOAH website.
If you are not the prescribing veterinary surgeon, advice should be sought from the medicine prescriber.
Date of preparation: January 2018
References
† Bravecto is the only product to provide 12 weeks* flea and tick protection from a single spot-on and chew.
* Bravecto Chew provides 12-week immediate and persistent killing activity against fleas (Ctenocephalides felis), 12-week immediate and persistent killing activity against the ticks Ixodes ricinus, Dermacentor reticulatus and D. variabilis and 8-week immediate and persistent killing activity against Rhipicephalus sanguineus.
